IONS · Ionis Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $7.39B |
| P/E | — |
| Float | 164.5M |
| Beta | 0.41 |
| Volatility | 10.3% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 68 |
| Price | 44.88 |
| Change | +0.99% |
| Prev Close | 44.44 |
| Open | 46.75 |
| Day Low | 44.27 |
| Day High | 46.75 |
| Avg Vol | 5 |
| Avg $ Vol | $232.5M |
| 52W High | 86.74 |
| 52W Low | 44.27 |
| 52W Pos | 1.4% |
| From High | −48.26% |
| From Low | +1.38% |
| Max DD 1Y | −48.62% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −20.38% |
| SMA 50 | −19.82% |
| SMA 200 | −37.82% |
| RSI (14) | 25.4 |
| Vol 30D | 50.6% |
| Vol 90D | 61.4% |
| 1Y Range | 44–87 |
| Daily bars | 516 |
| Perf Week | −18.02% |
| Perf Month | −26.91% |
| Perf Quarter | −40.04% |
| Perf Half Y | −37.69% |
| Perf Year | −27.35% |
| Perf YTD | −43.67% |
| Prev Day | +0.99% |
| Clavix | B- |
| Debt / Eq | 4.77 |
| Curr Ratio | 3.83 |
| Int Cover | -8.4× |
| FCF Margin | 62.0% |
| Rev Growth | −40.7% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 22 / 35 |
Clavix risk grade
regraded every trading dayIONS grades B-, 68 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (45, fragile). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 22 of 35 in Biotechnology by Clavix score.
How rough the ride is
| IONS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.41 | 0.51 |
| Volatilityannualized | 10.3% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −48.6% | — |
| Typical daily movemedian absolute daily change | 1.29% | — |
| Days beyond ±3%of the last 252 sessions | 3815% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| IONS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.41 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| IONS | |
|---|---|
| 1 week | −18.0% |
| 1 month | −26.9% |
| Year to date | −43.7% |
| 1 year | −27.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| IONS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 8 Aug |
| Average score0 most bearish, 100 most bullish | 53 |
| Bullish · bearisharticles above 60 · below 40 | 13 · 11 |
| Directionarticles whose tone is improving vs worsening | 13 ↑ 11 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| IONS | |
|---|---|
| Revenue growthyear over year | −40.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openIonis Pharmaceuticals CEO Brett Monia spoke at the Morgan Stanley Global Healthcare Conference, highlighting recent regulatory wins and commercial progress for its drug TRYNGOLZA, while also acknowledging setbacks in late-stage cardiovascular studies.
Ionis Pharmaceuticals CEO Brett Monia spoke at the Morgan Stanley Global Healthcare Conference, highlighting two recent regulatory wins and commercial-launch progress for TRYNGOLZA, while also acknowledging setbacks in late-stage cardiovascular pipeline studies. The article text is truncated, so further details are not available.
Ionis Pharmaceuticals (IONS) is back in focus after partner Novartis reported that the Phase 3 Lp(a)HORIZON trial of pelacarsen failed to reduce major cardiovascular events such as heart attacks and strokes, even though it sharply lowered lipoprotein(a) levels (a cholesterol-like particle tied to heart disease risk). IONS shares have fallen about 16% over the past 7 days and about 22% over the past 30 days, though the 5-year total shareholder return is still up 25.67%.
On September 5, 2026, Reuters reported that pelacarsen, an experimental cholesterol drug from Novartis and Ionis, failed to reduce heart attacks, strokes, and related cardiovascular events in a late-stage trial of more than 8,000 patients, even though it did lower the targeted cholesterol particle called Lp(a).
Ionis received FDA approval for Zanvastro (zilganersen), its first independently launched neurology drug, to treat Alexander disease in adults and children. The drug is priced at $285,000 per dose and is projected to generate more than $100 million in annual sales at its peak, though the patient population is fewer than 1,000 people in the U.S.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CGON | CG Oncology Inc | B- | $6.61B | — | 0.21 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.47B | 80.58 | 0.39 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.71B | 19.72 | 1.90 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $9.25B | 111.61 | 1.18 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $9.39B | — | 1.33 | Compare |
| CYTK | Cytokinetics Inc | B | $9.56B | — | 0.40 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.97B | 41.27 | 0.56 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.